CTLA4 and myocarditis: Rates of ICI myocarditis have increasingly been reported and development of ICI‐myocarditis alone is associated with high rate of (upwards of 50%) mortality, with more severe ICI‐myocarditis associated with the combined use of anti‐PD1 and CTLA‐4 therapies.12, 13